Why is EGFR considered a major target in cancer therapy?

EGFR is a major target because activating mutations or amplification can create strong tumor dependence on EGFR signaling. This makes EGFR-mutant cancers, especially some non-small cell lung cancers, highly responsive to tyrosine kinase inhibitors until resistance pathways emerge.

How do PARP inhibitors work in precision oncology?

PARP inhibitors exploit synthetic lethality in tumors with homologous recombination defects, such as BRCA1 or BRCA2 loss. By blocking PARP-mediated repair and trapping PARP on DNA, these drugs convert repair stress into lethal DNA damage in repair-deficient cancer cells.

Why has KRAS historically been difficult to target?

KRAS was long considered difficult to drug because it binds nucleotides very tightly and has a relatively smooth protein surface. The discovery of targetable pockets, especially the switch-II pocket in KRAS G12C, changed that and enabled a new class of allele-specific inhibitors.

How are VEGF and CTLA4 different from receptor tyrosine kinase targets?

VEGF and CTLA4 are central to the tumor microenvironment rather than serving primarily as direct intracellular growth drivers. VEGF regulates angiogenesis and vascular permeability, while CTLA4 suppresses antitumor immune activation, making both critical for combination therapy design.

What is the biggest challenge in targeted oncology today?

A major challenge is adaptive resistance. Tumors often escape targeted therapies through secondary mutations, pathway redundancy, lineage plasticity, or microenvironmental support, which is why combination strategies and biomarker-guided treatment sequencing are increasingly important.

8 Key Molecular Targets in Precision Oncology: EGFR, PARP1, KRAS, HER2

Q: What are the most important molecular targets in precision oncology?

Among the most influential molecular targets in precision oncology are EGFR, PARP1, KRAS, HER2, ALK, MET, VEGF, and CTLA4. Together they represent growth signaling, DNA repair, angiogenesis, and immune regulation pathways that drive tumor progression and therapeutic response.

Precision oncology is built on the idea that tumors depend on a limited set of actionable molecular vulnerabilities. Understanding those vulnerabilities helps researchers and clinicians match mechanism-driven therapies to tumor biology, anticipate resistance, and design better combination strategies.

Introduction
Why Molecular Targets Matter in Precision Oncology
EGFR: A Central Driver of Receptor Tyrosine Kinase Signaling
PARP1: A Synthetic Lethality Target in DNA Repair–Dependent Tumors
KRAS: One of the Most Challenging Oncogenic Drivers
HER2: A Signal Amplifier in Tumor Progression
ALK: A Fusion-Driven Kinase Hub
MET: A Key Mediator of Invasion and Metastasis
VEGF: The Master Regulator of Tumor Angiogenesis
CTLA4: A Core Checkpoint in Tumor Immune Evasion
Key Takeaways for Oncology Research
Frequently Asked Questions
References

Introduction

Cancer treatment has shifted from broadly cytotoxic regimens toward targeted strategies designed around specific molecular lesions. This change reflects a central principle of precision oncology: recurrent alterations such as mutations, amplifications, fusions, epigenetic dysregulation, and microenvironmental rewiring can create therapeutic dependencies within tumors. Intervening at those nodes can alter malignant signaling, restore apoptotic sensitivity, and improve the therapeutic index compared with less selective approaches.

That framework has been strengthened by next-generation sequencing, single-cell and spatial multi-omics, and structural biology. Together, these tools reveal not only which genes are altered, but how those alterations reshape signaling networks over time. The source draft identifies eight representative targets as especially informative for understanding the logic of modern targeted therapy: EGFR, PARP1, KRAS, HER2, ALK, MET, VEGF, and CTLA4. These targets span growth-factor signaling, DNA repair, angiogenesis, and immune regulation.

Why Molecular Targets Matter in Precision Oncology

These eight targets illustrate why molecular taxonomy increasingly matters as much as, and sometimes more than, tissue of origin. Receptor tyrosine kinases such as EGFR, HER2, ALK, and MET drive proliferation and survival through highly druggable signaling circuits. PARP1 exposes how DNA repair dependency can be transformed into a therapeutic liability. KRAS demonstrates the difficulty of shutting down a central intracellular signaling switch. VEGF and CTLA4 highlight the importance of the tumor microenvironment, including vasculature and immune suppression. The source article also emphasizes three recurring ideas: structure determines druggability, tumor networks adapt under pressure, and biomarkers guide both response and resistance.

EGFR: A Central Driver of Receptor Tyrosine Kinase Signaling

EGFR is one of the clearest examples of oncogene addiction in solid tumors. Ligand-induced dimerization activates downstream RAS–RAF–MEK–ERK and PI3K–AKT–mTOR signaling, linking extracellular growth cues to proliferation and survival. In tumors, activating alterations such as exon 19 deletions, L858R substitutions, amplification, and extracellular variants like EGFRvIII can create sustained, ligand-independent signaling.

From a therapeutic standpoint, EGFR also provides a classic model of stepwise resistance. Early EGFR TKIs produced strong responses in EGFR-mutant NSCLC, but gatekeeper alterations such as T790M reduced inhibitor sensitivity by restoring ATP affinity. Third-generation inhibitors such as osimertinib addressed that problem, yet resistance still emerges through C797S and bypass signaling via MET or HER2. The source text points toward structure-guided next-generation inhibitors, bispecific EGFR/MET targeting, and vertical pathway combinations as the next strategic layer.[1]

PARP1: A Synthetic Lethality Target in DNA Repair–Dependent Tumors

PARP1 is central to base excision repair and chromatin-associated DNA damage sensing. In homologous recombination-deficient tumors, especially those with BRCA1 or BRCA2 loss, PARP1 becomes a key vulnerability. Inhibiting PARP1 blocks repair signaling and can trap PARP1 on DNA, converting manageable repair intermediates into replication-associated damage that HR-deficient cells cannot resolve efficiently.

This is why PARP inhibitors became one of the best clinical demonstrations of synthetic lethality in oncology. The source article highlights their relevance across ovarian, breast, pancreatic, and prostate cancer while also noting predictable resistance mechanisms, including BRCA reversion, replication fork protection, altered end-joining balance, and transporter-mediated drug handling. It further suggests logically matched combinations with ATR, CHK1, WEE1, DNA-PK, and immunotherapy to expand benefit beyond classical BRCA-mutant settings.[2]

KRAS: One of the Most Challenging Oncogenic Drivers

KRAS sits at the center of growth signaling and controls multiple downstream pathways, including RAF–MEK–ERK, PI3K–AKT–mTOR, and RAL-mediated programs. Mutations in codons 12, 13, and 61 impair GTP hydrolysis and maintain KRAS in an active state, driving proliferation, metabolic rewiring, and apoptosis resistance. The source text notes its especially high prevalence in pancreatic ductal adenocarcinoma, along with major roles in colorectal and lung adenocarcinoma.

For years, KRAS was labeled undruggable, but that narrative changed with discovery of the switch-II pocket in KRAS G12C. Even so, the draft makes clear that single-agent KRAS inhibition rarely ends the story. Resistance can emerge through secondary mutations, amplification, or upstream feedback via receptor tyrosine kinases and SHP2. That is why the field now focuses on combination control, including KRAS inhibitors paired with SHP2, SOS1, MEK, or immunotherapy, alongside newer approaches such as allele-selective inhibitors, degraders, and siRNA-based strategies.

HER2: A Signal Amplifier in Tumor Progression

HER2 differs from some other ErbB family members because it is predisposed to signaling through heterodimerization even without a classical ligand-driven activation pattern. Amplification or overexpression therefore creates a highly efficient signaling amplifier that drives PI3K/AKT and MAPK output in breast, gastric, gastroesophageal, and other tumor types.

The therapeutic evolution of HER2-targeted therapy also shows how precision oncology can diversify beyond one drug class. Antibodies such as trastuzumab and pertuzumab, TKIs such as lapatinib and neratinib, and ADCs such as T-DM1 and trastuzumab deruxtecan all target the same axis in different ways. The source article identifies resistance mechanisms including p95HER2, PI3K-pathway activation, and reduced antibody-mediated immune effector function, and points to next-generation ADCs and pathway-based combinations as important next steps.[4]

ALK: A Fusion-Driven Kinase Hub

ALK is most relevant in cancer when fusion events create constitutively active chimeric kinases, especially EML4–ALK in NSCLC. These fusions sustain JAK/STAT, PI3K/AKT, and MAPK signaling and define a patient subset that is unusually sensitive to kinase inhibition. The source text also notes the clinical importance of CNS penetration because ALK-rearranged disease often involves brain metastases.

The therapeutic pattern again reflects iterative resistance management. Crizotinib validated the target, but later generations improved both potency and brain penetration. Alectinib, ceritinib, brigatinib, and lorlatinib progressively widened mutation coverage, including difficult solvent-front alterations such as G1202R. Still, compound mutations, lineage plasticity, and bypass signaling mean that durable control may require rational ALK-based combinations rather than serial monotherapy alone.[5]

MET: A Key Mediator of Invasion and Metastasis

MET links growth signaling to invasion, motility, morphogenesis, and metastatic behavior. Its oncogenic activation can occur through amplification, activating mutations, overexpression, or exon 14 skipping that reduces receptor degradation. As the source draft explains, this makes MET both a primary oncogenic driver and a common bypass pathway after other targeted therapies, especially EGFR inhibition.

Clinically, MET-targeted drugs have shown meaningful activity in tumors with MET exon 14 alterations, but resistance remains a recurring issue through kinase-domain substitutions, ERBB or KRAS pathway activation, and ligand-mediated signaling loops. The source text frames MET as an especially strong candidate for combination treatment with EGFR inhibitors, VEGF-directed strategies, or immunotherapy because of its roles in invasion and immune exclusion.[6]

VEGF: The Master Regulator of Tumor Angiogenesis

VEGF remains one of the most important non-oncogene targets in cancer biology because it orchestrates angiogenesis, vascular permeability, and delivery conditions within the tumor microenvironment. Hypoxia-driven VEGF expression supports vessel formation, but excess signaling also creates abnormal vasculature that can impede drug delivery and immune infiltration.

That is why anti-angiogenic therapy has evolved from a vessel-destruction concept toward the idea of vascular normalization. The source article highlights bevacizumab and VEGFR-directed TKIs as tools not only for suppressing angiogenesis but also for making tumors more permissive to cytotoxic therapy and immunotherapy. Its mention of time-sequenced combinations underscores a practical point for researchers: timing may matter as much as target choice when combining anti-VEGF agents with immune-based strategies.[7]

CTLA4: A Core Checkpoint in Tumor Immune Evasion

CTLA4 represents a different dimension of precision oncology: modulation of immune tolerance rather than direct inhibition of tumor-intrinsic growth pathways. By competing with CD28 for B7 ligands, CTLA4 limits co-stimulation and restrains T-cell activation. In tumors, it helps maintain immune escape both by suppressing effector responses and by supporting regulatory T-cell activity.

The source draft emphasizes that anti-CTLA4 therapy works through more than one mechanism. Ipilimumab and related antibodies can relieve inhibitory signaling on effector T cells while also depleting intratumoral Tregs depending on Fc properties. Combination therapy with PD-1 blockade improves activity in several tumors, although toxicity rises as well. This makes CTLA4 a strong example of how antibody engineering, dosing strategy, and checkpoint combinations are becoming more refined and mechanism-specific.[8]

Key Takeaways for Oncology Research

The original draft closes with a strong systems-level message: these targets are best understood not as isolated stories, but as interacting modules within a broader therapeutic network. Structure-guided drug design, adaptive resistance, and biomarker-driven treatment selection remain the central threads connecting all eight programs. Future progress will likely depend on deeper integration of structural biology, multi-omics profiling, liquid biopsy, and AI-assisted molecular design to guide both drug development and therapeutic sequencing.

EGFR, HER2, ALK, and MET define growth-factor dependency; PARP1 defines DNA repair vulnerability; KRAS defines pathway integration and adaptive resistance; and VEGF plus CTLA4 define how vasculature and immunity shape treatment response. Together, they form a practical map of contemporary precision oncology.

Frequently Asked Questions

1. What are the most important molecular targets in precision oncology?

Key targets include EGFR, PARP1, KRAS, HER2, ALK, MET, VEGF, and CTLA4 because they represent major therapeutic entry points across receptor signaling, DNA repair, angiogenesis, and immune regulation.

2. Why is EGFR so important in targeted cancer therapy?

EGFR is important because certain tumors become highly dependent on EGFR-driven signaling. That dependence can create dramatic sensitivity to EGFR inhibitors, especially in mutation-defined subsets such as EGFR-mutant NSCLC.

3. How do PARP inhibitors fit into precision oncology?

PARP inhibitors are used to exploit synthetic lethality in tumors with homologous recombination defects, particularly BRCA-associated cancers. They work by disrupting repair and increasing lethal DNA damage in repair-deficient cells.

4. Why has KRAS been considered difficult to target?

KRAS binds nucleotides with very high affinity and historically lacked obvious drug-binding pockets. New insights into the switch-II pocket changed that, but resistance and pathway feedback still limit single-agent durability.

5. What makes HER2-directed therapy different from HER2 overexpression alone?

HER2 overexpression identifies a biologic dependency, but HER2-directed therapy now spans multiple modalities, including monoclonal antibodies, TKIs, and antibody-drug conjugates. This broader toolkit improves disease control and can address diverse resistance mechanisms.

6. Why are VEGF and CTLA4 important for combination therapy design?

VEGF and CTLA4 shape the tumor microenvironment. VEGF influences vascular architecture and immune access, while CTLA4 suppresses effective T-cell activation. Together, they help explain why combination regimens can outperform single-pathway approaches.

References

[1] Zhang H., et al. Structural mechanisms of EGFR activation and resistance to tyrosine kinase inhibitors. Pharmacological Reviews 77(1), 1–38 (2025).
[2] Fong P.C., Lord C.J. & Ashworth A. Synthetic lethality revisited: PARP1 inhibition and the evolving landscape of DNA repair–targeted therapy. Biochemical Pharmacology 217, 115758 (2025).
[3] Lito P., Hallin J. & McCormick F. KRAS inhibition enters the clinic: mechanisms, resistance, and combination strategies. Journal of Hematology & Oncology 16, 121 (2023).
[4] Swain S.M., Cortés J. & Baselga J. Two decades of HER2-targeted therapy: biology, resistance, and next-generation antibody–drug conjugates. Cancer Research 85(4), 712–732 (2025).
[5] Soda M., Takeuchi K. & Shaw A.T. The evolving structural biology of ALK fusions and next-generation inhibition. Nature Reviews Cancer 25, 150–170 (2025).
[6] Hamada K., et al. Targeting MET exon 14 skipping and beyond: therapeutic strategies and immune modulation. Nature Reviews Clinical Oncology 21, 312–331 (2024).
[7] Ferrara N., Adamis A.P. & Carmeliet P. VEGF and the paradigm of vascular normalization in oncology. Pharmaceuticals 17(2), 240–263 (2024).
[8] Postow M.A., Hellmann M.D. & Wolchok J.D. CTLA-4 blockade: mechanisms of action, clinical progress, and next-generation antibody design. Immunotherapy Advances 5(1), itae012 (2024).